{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T04:24:36Z","timestamp":1771561476455,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["#75N95021C00034"],"award-info":[{"award-number":["#75N95021C00034"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["#75N95021C00034"],"award-info":[{"award-number":["#75N95021C00034"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["#75N95021C00034"],"award-info":[{"award-number":["#75N95021C00034"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["#75N95021C00034"],"award-info":[{"award-number":["#75N95021C00034"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Individuals with opioid use disorder face barriers accessing first-line pharmacotherapy. Home delivery interventions have been shown to improve medication adherence for other chronic diseases, but the relationship between buprenorphine home delivery and opioid use disorder treatment outcomes has not been assessed. We evaluated the association between medication home delivery and retention in treatment in a feasibility study of adults who initiated telemedicine treatment for opioid use disorder and received one or more prescriptions. We described the characteristics of patients and estimated the odds of attending a telemedicine visit three and six months after enrollment as a function of home delivery use using logistic regression. The sample consisted of 337 adults with the following characteristics: mean age 40.8 years (SD 10.1), 51.0% male, and 70.9% commercially insured. In the first 30 days of treatment 6.8% (<jats:italic>n<\/jats:italic>\u2009=\u200923) of patients used home delivery. At three months, the percentages of individuals retained among those with and without home delivery were 82.6% and 58.9%, respectively (odds ratio [OR]: 3.31, 95% confidence interval [CI]: 1.10\u20139.96). At six months, the percentages of individuals retained among those with and without home delivery were 78.6% and 45.5%, respectively (OR: 4.39, 95% CI: 1.19\u201316.25, <jats:italic>n<\/jats:italic>\u2009=\u2009203). Although uptake of medication delivery through the pharmacy partner was low within this sample of patients receiving treatment for opioid use disorder, its use was associated with increased retention in care at three and six months. Given the small sample size, low uptake, and limited statistical power, additional research is warranted.<\/jats:p>","DOI":"10.1186\/s13722-025-00545-2","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T01:29:35Z","timestamp":1739323775000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Early findings on home delivery of buprenorphine and retention in treatment for opioid use disorder"],"prefix":"10.1186","volume":"20","author":[{"given":"Marlene C.","family":"Lira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren E.","family":"Hendy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alisha","family":"Liakas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Turanchik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clare","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Jimes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Justin Coffey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"545_CR1","unstructured":"Department of Justice Drug Enforcement Administration. Federal Register. 2024 [cited 2025 Jan 13]. Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications. Available from: https:\/\/www.federalregister.gov\/documents\/2024\/11\/19\/2024-27018\/third-temporary-extension-of-covid-19-telemedicine-flexibilities-for-prescription-of-controlled"},{"issue":"12","key":"545_CR2","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1001\/jamapsychiatry.2024.3076","volume":"81","author":"EL Winstanley","year":"2024","unstructured":"Winstanley EL, Gray A, Thornton D. Addressing the escalating problems that patients Encounter when filling Buprenorphine prescriptions. JAMA Psychiatry. 2024;81(12):1167\u20138.","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"545_CR3","doi-asserted-by":"publisher","first-page":"e241077","DOI":"10.1001\/jamahealthforum.2024.1077","volume":"5","author":"PR Freeman","year":"2024","unstructured":"Freeman PR, Hammerslag LR, Ahrens KA, Sharbaugh M, Gordon AJ, Austin AE, et al. Barriers to Buprenorphine dispensing by Medicaid-Participating Community Retail pharmacies. JAMA Health Forum. 2024;5(5):e241077.","journal-title":"JAMA Health Forum"},{"issue":"4","key":"545_CR4","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/ADM.0000000000000762","volume":"15","author":"B Ostrach","year":"2021","unstructured":"Ostrach B, Carpenter D, Cote LP. DEA Disconnect leads to Buprenorphine bottlenecks. J Addict Med. 2021;15(4):272\u20135.","journal-title":"J Addict Med"},{"key":"545_CR5","doi-asserted-by":"publisher","first-page":"109518","DOI":"10.1016\/j.drugalcdep.2022.109518","volume":"237","author":"LG Hill","year":"2022","unstructured":"Hill LG, Loera LJ, Torrez SB, Puzantian T, Evoy KE, Ventricelli DJ, et al. Availability of buprenorphine\/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states. Drug Alcohol Depend. 2022;237:109518.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"545_CR6","doi-asserted-by":"publisher","first-page":"e2316089","DOI":"10.1001\/jamanetworkopen.2023.16089","volume":"6","author":"SG Weiner","year":"2023","unstructured":"Weiner SG, Qato DM, Faust JS, Clear B. Pharmacy availability of Buprenorphine for Opioid Use Disorder Treatment in the US. JAMA Netw Open. 2023;6(5):e2316089.","journal-title":"JAMA Netw Open"},{"key":"545_CR7","doi-asserted-by":"publisher","first-page":"108729","DOI":"10.1016\/j.drugalcdep.2021.108729","volume":"224","author":"NJ Kazerouni","year":"2021","unstructured":"Kazerouni NJ, Irwin AN, Levander XA, Geddes J, Johnston K, Gostanian CJ, et al. Pharmacy-related buprenorphine access barriers: an audit of pharmacies in counties with a high opioid overdose burden. Drug Alcohol Depend. 2021;224:108729.","journal-title":"Drug Alcohol Depend"},{"key":"545_CR8","doi-asserted-by":"publisher","first-page":"103703","DOI":"10.1016\/j.drugpo.2022.103703","volume":"105","author":"L Textor","year":"2022","unstructured":"Textor L, Ventricelli D, Aronowitz SV. Red flags and red tape: Telehealth and pharmacy-level barriers to buprenorphine in the United States. Int J Drug Policy. 2022;105:103703.","journal-title":"Int J Drug Policy"},{"issue":"8","key":"545_CR9","first-page":"851","volume":"20","author":"RN Iyengar","year":"2014","unstructured":"Iyengar RN, Balagere DS, Henderson RR, LeFrancois AL, Rabbitt RM, Frazee SG. Association between dispensing channel and medication adherence among medicare beneficiaries taking medications to treat diabetes, high blood pressure, or high blood cholesterol. J Manag Care Spec Pharm. 2014;20(8):851\u201361.","journal-title":"J Manag Care Spec Pharm"},{"issue":"11","key":"545_CR10","first-page":"1247","volume":"22","author":"EV Fernandez","year":"2016","unstructured":"Fernandez EV, McDaniel JA, Carroll NV. Examination of the Link between Medication Adherence and Use of Mail-Order pharmacies in Chronic Disease States. J Manag Care Spec Pharm. 2016;22(11):1247\u201359.","journal-title":"J Manag Care Spec Pharm"},{"key":"545_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jns.2018.04.001","volume":"390","author":"WP Neil","year":"2018","unstructured":"Neil WP, Shiokari CE, Burchette RJ, Stapleton D, Ovbiagele B. Mail order pharmacy use and adherence to secondary prevention drugs among stroke patients. J Neurol Sci. 2018;390:117\u201320.","journal-title":"J Neurol Sci"},{"issue":"1","key":"545_CR12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12954-024-01118-3","volume":"21","author":"M Pacheco","year":"2024","unstructured":"Pacheco M, Ologunowa A, Jacobson A. Analysis of different populations accessing online overdose response training and harm reduction supplies (ADORES). Harm Reduct J. 2024;21(1):202.","journal-title":"Harm Reduct J"},{"issue":"12","key":"545_CR13","first-page":"1890","volume":"29","author":"MC Lira","year":"2023","unstructured":"Lira MC, Jimes C, Coffey MJ. Retention in Telehealth Treatment for Opioid Use Disorder among Rural populations: a retrospective cohort study. Telemed J E-Health off J Am Telemed Assoc. 2023;29(12):1890\u20136.","journal-title":"Telemed J E-Health off J Am Telemed Assoc"},{"issue":"2","key":"545_CR14","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1016\/j.amepre.2021.02.017","volume":"61","author":"D Do","year":"2021","unstructured":"Do D, Geldsetzer P. Trends in Mail-Order Pharmacy Use in the U.S. from 1996 to 2018: an analysis of the Medical Expenditure Panel Survey. Am J Prev Med. 2021;61(2):e63\u201372.","journal-title":"Am J Prev Med"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00545-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-025-00545-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00545-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T04:55:12Z","timestamp":1757134512000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-025-00545-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["545"],"URL":"https:\/\/doi.org\/10.1186\/s13722-025-00545-2","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"assertion":[{"value":"22 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors\u2019 names in citation details have been corrected from \u201cC. Lira, M., E. Hendy, L., Liakas, A. et al.\u201d to \u201cLira, M. C, Hendy, L. E., Liakas, A. et al.\u201d.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved through expedited review by an external IRB (Solutions IRB; FWA00021831). The pharmacy partnership was developed with 513(g) exemption from the Food and Drug Administration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MJC, MCL, and LT are equity owners in Workit Health. MJC receives author royalties from UpToDate and Medlink Neurology unrelated to this work. LEH, AL, CP, and CJ have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}